Grace Therapeutics, Inc. Share-based Payment Arrangement, Expense
Grace Therapeutics, Inc. (GRCE) reported Share-based Payment Arrangement, Expense of $326 for the 3-month period ending 2023-12-31, per its 10-Q filed 2024-02-12.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2024-02-12
- Grace Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2023-12-31 was $326.00, a 26.41% decline year-over-year.
- Grace Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2023-09-30 was $280.00, a 51.89% decline year-over-year.
- Grace Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2023-06-30 was $78.00K, a 83.19% decline year-over-year.
- Grace Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2022-12-31 was $443.00.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month |
|---|---|---|---|
| 2023-12-31 | $326.00 10-Q · filed 2024-02-12 | $606.00 derived: sum of 2 quarters · filed 2024-02-12 | $684.00 10-Q · filed 2024-02-12 |
| 2023-09-30 | $280.00 10-Q · filed 2023-11-13 | $358.00 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $78.00K 10-Q · filed 2023-08-11 | ||
| 2022-12-31 | $443.00 10-Q · filed 2024-02-12 | $1.02K derived: sum of 2 quarters · filed 2024-02-12 | $1.49K 10-Q · filed 2024-02-12 |
| 2022-09-30 | $582.00 10-Q · filed 2023-11-13 | $1.05K 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $464.00K 10-Q · filed 2023-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |